REDWOOD CITY, Calif., Feb. 11, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Barry Selick, chief executive officer of Threshold, will present at the BIO CEO & Investor Conference on Wednesday, February 13, 2008 at 2:00 p.m. ET. Dr. Selick will provide a general update on the Company including its Hypoxia-Activated Prodrug, TH-302, for the potential treatment of solid tumors.
The live and archived webcast of the presentation can be accessed under "Webcasts" on the Company's website, or by directly linking to http://investor.thresholdpharm.com/medialist.cfm. The archived replay will be available on the Threshold website for one month following the conference.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs. For additional information, please visit our website (http://www.thresholdpharm.com).